The National Comprehensive Cancer Network (NCCN) has expanded the indications for molecular testing for EGFR and ALK to other types of NSCLC, not otherwise specified (NOS) NSCLC, as well as to patients with metastatic disease and squamous LC who are non-smokers [11]. The gene discussed is EGFR; the disease is non-small cell lung carcinoma.